269. Pyogenic arthritis Clinical trials / Disease details
Clinical trials : 23 / Drugs : 30 - (DrugBank : 12) / Drug target genes : 15 - Drug target pathways : 106
Showing 1 to 10 of 23 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04901325 (ClinicalTrials.gov) | September 29, 2021 | 17/5/2021 | Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) | Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG) | Pyoderma Gangrenosum;Skin Diseases;Wound Heal;Pyoderma;Skin Ulcer | Drug: Baricitinib | Oregon Health and Science University | NULL | Suspended | 18 Years | 99 Years | All | 20 | Phase 2 | United States |
| 2 | NCT05120726 (ClinicalTrials.gov) | June 2, 2021 | 11/9/2021 | A Novel Therapeutic Treatment of Pyoderma Gangrenosum | A Novel Therapeutic Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Biological: Dehydrated human amnion/chorion membrane | Louisiana State University Health Sciences Center in New Orleans | NULL | Recruiting | 18 Years | N/A | All | 20 | Phase 4 | United States |
| 3 | NCT04895566 (ClinicalTrials.gov) | May 24, 2021 | 17/5/2021 | Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderm ... | Phase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe Pyoderma Phase 0/1 Topical Application of the Monoclonal Antibody (Mab) sB24M in Patients With Severe Pyoderm ... | Pyoderma;Pyoderma Gangrenosum;Pyoderma Vegetans;Pyoderma Gangrenosum Surrounding Surgical Stoma | Biological: Monoclonal antibody (Mab) sB24M | SWISS BIOPHARMA MED GmbH | NULL | Active, not recruiting | 21 Years | 80 Years | All | 10 | Early Phase 1 | Belarus;Latvia |
| 4 | NCT04274166 (ClinicalTrials.gov) | May 2021 | 12/2/2020 | Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum | The Efficacy and Safety of Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: secukinumab 150 mg (2 injections per dose | Wake Forest University Health Sciences | Novartis | Withdrawn | 18 Years | 75 Years | All | 0 | Phase 2 | United States |
| 5 | EUCTR2020-003273-21-PL (EUCTR) | 09/11/2020 | 08/09/2020 | NA | Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating subjects with Pyoderma Gangrenosum (OPTIMA). - Exploratory study of IFX-1 in Subjects with Pyoderma Gangrenosum Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating s ... | Pyoderma gangrenosum MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Pyoderma gangrenosum MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gang ... | Product Name: IFX-1 Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody Product Name: IFX-1 Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody Product Name: IFX-1 Other descriptive name: Anti-(complement C5a) IgG4 chimeric monoclonal antibody Pr ... | InflaRx GmbH | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 2 | United States;Poland | ||
| 6 | NCT03311464 (ClinicalTrials.gov) | October 27, 2017 | 12/10/2017 | A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosumin ... | A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Acti ... | Pyoderma Gangrenosum | Drug: adalimumab | AbbVie | NULL | Completed | 18 Years | N/A | All | 22 | Phase 3 | Japan |
| 7 | NCT03072953 (ClinicalTrials.gov) | June 7, 2017 | 17/2/2017 | Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum | A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (AP ... | Pyoderma Gangrenosum | Drug: APD334 | Arena Pharmaceuticals | NULL | Terminated | 18 Years | 80 Years | All | 2 | Phase 2 | Australia;New Zealand |
| 8 | NCT03137160 (ClinicalTrials.gov) | May 4, 2017 | 27/4/2017 | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Biological: Ixekizumab | Ohio State University | Eli Lilly and Company | Completed | 18 Years | N/A | All | 5 | Phase 2 | United States |
| 9 | NCT02733094 (ClinicalTrials.gov) | April 2016 | 28/3/2016 | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoder ... | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoder ... | Pyoderma Gangrenosum | Drug: Secukinumab | Technische Universität München | Novartis | Active, not recruiting | 18 Years | 75 Years | All | 8 | Phase 1/Phase 2 | Germany |
| 10 | EUCTR2015-000762-65-DE (EUCTR) | 09/07/2015 | 25/06/2015 | Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosu Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoder ... | Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoder ... | Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising. MedDRA version: 20.0;Level: PT;Classification code 10037635;Term: Pyoderma gangrenosum;System Organ Class: 10040785 - Skin and subcutaneous tissue disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Pyoderma gangrenosumis an autoinflammatory disease, characterized by relapsing, painful ulcers of th ... | Trade Name: Cosentyx® Product Name: Cosentyx Product Code: EU/1/14/980/002; EU/1/14/980/003 | Technische Universität München, School of Medicine, represented by Dean | NULL | Not Recruiting | Female: yes Male: yes | 7 | Phase 2;Phase 3 | Germany |